ESMO 2023 | The emerging role of MRD in solid tumor management

Klaus Pantel, MD, PhD, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, provides an overview of the latest developments in minimal residual disease (MRD) testing in solid tumors. There are multiple benefits of MRD testing, such as the ability to detect relapse as early as possible, leading to earlier interventions and the prevention of metastasis. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.